Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sharon Benzeno Sells 154,768 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Sharon Benzeno sold 154,768 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $21.14, for a total transaction of $3,271,795.52. Following the transaction, the insider owned 221,278 shares in the company, valued at approximately $4,677,816.92. This trade represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sharon Benzeno also recently made the following trade(s):

• On Friday, June 26th, Sharon Benzeno sold 11,034 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $21.00, for a total transaction of $231,714.00.

Adaptive Biotechnologies Stock Performance

Adaptive Biotechnologies stock traded up $0.05 during midday trading on Tuesday, hitting $21.45. 3,421,196 shares of the company’s stock were exchanged, compared to its average volume of 3,848,816. The stock has a market cap of $3.43 billion, a price-to-earnings ratio of -65.00 and a beta of 2.15. Adaptive Biotechnologies Corporation has a 12-month low of $9.96 and a 12-month high of $21.64. The firm’s 50 day simple moving average is $15.66 and its 200 day simple moving average is $15.74.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. The business had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The business’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.20) earnings per share. On average, equities research analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Adaptive Biotechnologies

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd acquired a new position in shares of Adaptive Biotechnologies in the 4th quarter valued at $28,000. EverSource Wealth Advisors LLC lifted its stake in shares of Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after purchasing an additional 1,565 shares in the last quarter. KBC Group NV purchased a new stake in shares of Adaptive Biotechnologies during the 1st quarter worth about $45,000. Assetmark Inc. increased its position in Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new stake in Adaptive Biotechnologies during the 4th quarter worth approximately $51,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ADPT shares. TD Cowen upped their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Morgan Stanley dropped their target price on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. JPMorgan Chase & Co. reduced their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Finally, Wall Street Zen lowered Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Adaptive Biotechnologies currently has an average rating of “Moderate Buy” and an average price target of $20.50.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.